{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086103","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.676918+00:00","generated_at":"2026-05-31T12:29:25.001515+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY","bullets":["Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.","Non-GAAP adjusted diluted EPS $1.12 (down 15% YoY); GAAP diluted EPS $0.75 (down 21%).","Women's Health +3%, Biosimilars +22% driven by Hadlima launch; Established Brands -1% ex-FX.","FY2024 revenue guidance narrowed to $6.25-6.45B; Adjusted EBITDA margin reaffirmed 31-33%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086103","json":"https://secwatch.observer/filing/0001104659-24-086103.json","markdown":"https://secwatch.observer/filing/0001104659-24-086103.md","text":"https://secwatch.observer/filing/0001104659-24-086103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/0001104659-24-086103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/tm2420930d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:29:25.001515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}